Kvolik 2012b.
| Methods |
Study design: prospective, randomized study Sample size calculation: no information available |
|
| Participants |
Number of randomized participants: 24 Inclusion criteria: euthyroid, undergoing general anaesthesia for thyroidectomy Exclusion criteria: no information available |
|
| Interventions |
Anaesthesia: propofol and fentanyl NMBA: single intubating dose: rocuronium 0.6 mg/kg; maintenance dose: rocuronium 0.1 mg/kg Comparison: neostigmine 50 µg/kg vs sugammadex 2 mg/kg Administration time of sugammadex or neostigmine: end of surgery |
|
| Outcomes | Thyroid hormones (FT3, FT4, and TSH) measured before surgery, 1 hour after reversal, and 24 hours after surgery | |
| Notes |
Publication type: meeting abstract Country: Croatia Conversions: none Authors’ conclusions: Sugammadex treatment did not change levels of thyroid hormones and may be safely used in patients undergoing total thyroidectomy Contact: first trial author Slavica Kvolik contacted by e‐mail: slavica.kvolik@os.t‐com.hr on 24.05.2016; no reply received |
|
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | "Randomized study"; no further information available |
| Allocation concealment (selection bias) | Unclear risk | Unable to assess owing to insufficient information |
| Blinding of participants (performance bias) | Unclear risk | Unable to assess owing to insufficient information |
| Blinding of personnel (performance bias) | Unclear risk | Unable to assess owing to insufficient information |
| Blinding of primary outcome assessment (detection bias) | Unclear risk | Unable to assess owing to insufficient information |
| Blinding of safety assessment (detection bias) | Unclear risk | Unable to assess owing to insufficient information |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Unable to assess owing to insufficient information |
| Selective reporting (reporting bias) | Low risk | Study protocol not available, but published meeting abstract clearly includes all expected outcomes |
| Funding bias | Unclear risk | Unable to assess owing to insufficient information |
| Other bias | Unclear risk | No information on sample size calculation. No differences regarding participant characteristics and drug consumption between groups |